AVNS RSI Chart
Last 7 days
4.3%
Last 30 days
9.1%
Last 90 days
6.4%
Trailing 12 Months
-10.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 663.9M | 0 | 0 | 0 |
2023 | 697.5M | 696.0M | 695.0M | 689.5M |
2022 | 603.7M | 588.2M | 576.4M | 703.1M |
2021 | 715.1M | 737.8M | 736.2M | 587.0M |
2020 | 713.8M | 705.3M | 719.6M | 714.8M |
2019 | 660.1M | 671.4M | 677.7M | 697.6M |
2018 | 622.3M | 634.1M | 648.7M | 652.3M |
2017 | 577.5M | 588.9M | 600.3M | 611.6M |
2016 | 523.3M | 537.6M | 551.9M | 566.2M |
2015 | 1.7B | 1.6B | 1.6B | 509.0M |
2014 | 1.7B | 1.7B | 1.7B | 1.7B |
2013 | 0 | 0 | 1.7B | 1.7B |
2012 | 0 | 0 | 0 | 1.7B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 18, 2024 | holbrook kerr | acquired | - | - | 2,531 | svp, chief commercial officer |
Mar 18, 2024 | woody joseph fralin | acquired | - | - | 15,821 | chief executive officer |
Mar 18, 2024 | woody joseph fralin | sold (taxes) | -644,574 | 19.09 | -33,765 | chief executive officer |
Mar 18, 2024 | holbrook kerr | sold (taxes) | -68,647 | 19.09 | -3,596 | svp, chief commercial officer |
Mar 18, 2024 | greiner michael | sold (taxes) | -171,905 | 19.09 | -9,005 | svp - chief financial officer |
Mar 18, 2024 | greiner michael | acquired | - | - | 4,219 | svp - chief financial officer |
Mar 14, 2024 | greiner michael | sold | -152,980 | 19.1225 | -8,000 | svp - chief financial officer |
Mar 11, 2024 | shimer julie ann | bought | 9,925 | 19.85 | 500 | - |
Mar 06, 2024 | greiner michael | acquired | 1,100,000 | 19.14 | 57,471 | svp - chief financial officer |
Mar 06, 2024 | varshney sudhakar | sold (taxes) | -26,486 | 19.00 | -1,394 | svp, global supply chain |
Which funds bought or sold AVNS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | Clear Point Advisors Inc. | unchanged | - | -63.00 | 498 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -6.01 | -183,471 | 923,943 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -65.28 | -582,445 | 259,487 | -% |
May 16, 2024 | COMERICA BANK | reduced | -8.49 | -115,164 | 498,335 | -% |
May 16, 2024 | Tidal Investments LLC | new | - | 439,434 | 439,434 | 0.01% |
May 16, 2024 | Global Financial Private Client, LLC | unchanged | - | -42.00 | 294 | -% |
May 16, 2024 | Ancora Advisors LLC | unchanged | - | -48.00 | 378 | -% |
May 15, 2024 | Aquatic Capital Management LLC | sold off | -100 | -16,000 | - | -% |
May 15, 2024 | Anchor Investment Management, LLC | reduced | -67.35 | -780 | 319 | -% |
May 15, 2024 | Walleye Capital LLC | new | - | 620,455 | 620,455 | -% |
Unveiling Avanos Medical Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Avanos Medical Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.1M | 3.7M | -0.09 | 0.29 |
Avanos Medical Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 5.7% | 166 | 157 | 171 | 169 | 192 | 163 | 172 | 171 | 197 | 36.00 | 184 | 186 | 181 | 185 | 186 | 164 | 180 | 190 | 171 | 172 | 164 |
Gross Profit | 7.2% | 95.00 | 88.00 | 96.00 | 98.00 | 105 | 94.00 | 100 | 102 | 107 | 32.00 | 90.00 | 86.00 | 91.00 | 87.00 | 96.00 | 87.00 | 102 | 110 | 95.00 | 99.00 | 99.00 |
S&GA Expenses | 15.2% | 84.00 | 73.00 | 79.00 | 93.00 | 93.00 | 77.00 | 78.00 | 83.00 | 90.00 | 60.00 | 75.00 | 77.00 | 73.00 | 82.00 | 82.00 | 77.00 | 91.00 | 104 | 94.00 | 95.00 | 106 |
R&D Expenses | 6.1% | 7.00 | 7.00 | 6.00 | 7.00 | 8.00 | 7.00 | 7.00 | 8.00 | 8.00 | 6.00 | 8.00 | 8.00 | 8.00 | 10.00 | 8.00 | 8.00 | 9.00 | 8.00 | 10.00 | 10.00 | 10.00 |
EBITDA Margin | 5.3% | 0.09* | 0.08* | 0.09* | 0.11* | 0.12* | 0.13* | 0.09* | 0.07* | 0.04* | 0.00* | -0.03* | -0.04* | - | - | - | - | - | - | - | - | - |
Interest Expenses | -6.1% | 3.00 | 3.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
Income Taxes | 135.7% | 1.00 | -2.80 | 6.00 | -0.80 | 0.00 | 3.00 | -0.90 | 3.00 | 2.00 | 3.00 | 38.00 | -46.00 | -5.80 | -0.80 | -23.50 | -2.90 | -6.70 | -0.40 | -8.80 | -3.30 | -5.60 |
Earnings Before Taxes | -67.0% | 2.00 | 5.00 | -2.60 | -5.10 | -0.40 | 8.00 | 10.00 | 8.00 | 7.00 | -23.10 | 3.00 | -7.50 | -14.20 | -49.80 | -4.20 | - | - | -6.50 | -20.30 | -11.30 | -25.90 |
EBT Margin | 51.7% | 0.00* | -0.01* | 0.00* | 0.02* | 0.04* | 0.05* | 0.00* | -0.01* | -0.03* | -0.07* | -0.09* | -0.10* | - | - | - | - | - | - | - | - | - |
Net Income | -108.6% | -0.90 | 11.00 | -3.70 | -68.10 | -0.50 | 17.00 | 16.00 | 13.00 | 5.00 | 12.00 | -35.30 | 39.00 | -8.40 | -49.00 | 19.00 | -3.00 | 4.00 | -6.10 | -11.50 | -8.00 | -20.30 |
Net Income Margin | -4.5% | -0.09* | -0.09* | -0.08* | -0.05* | 0.06* | 0.07* | 0.08* | -0.01* | 0.03* | 0.01* | -0.07* | 0.00* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -163.0% | -8.00 | 13.00 | 29.00 | -2.60 | -6.80 | 34.00 | 28.00 | 27.00 | 2.00 | 52.00 | 23.00 | 15.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -1.8% | 1,661 | 1,692 | 1,725 | 1,667 | 1,735 | 1,787 | 1,775 | 1,753 | 1,767 | 1,604 | 1,598 | 1,683 | 1,649 | 1,673 | 1,799 | 1,756 | 1,764 | 1,800 | 1,808 | 1,783 | 1,834 |
Current Assets | -3.9% | 468 | 487 | 525 | 507 | 454 | 624 | 470 | 437 | 439 | 428 | 405 | 444 | 448 | 467 | 568 | 517 | 524 | 539 | 547 | 573 | 660 |
Cash Equivalents | -13.6% | 76.00 | 88.00 | 107 | 82.00 | 96.00 | 128 | 117 | 107 | 104 | 119 | 98.00 | 100 | 100 | 112 | 180 | 185 | 188 | 205 | 214 | 288 | 348 |
Inventory | 1.5% | 166 | 163 | 157 | 148 | 200 | 132 | 194 | 169 | 158 | 159 | 158 | 160 | 165 | 169 | 184 | 174 | 153 | 146 | 145 | 134 | 130 |
Net PPE | -0.9% | 116 | 117 | 117 | 123 | 164 | 119 | 163 | 164 | 167 | 168 | 170 | 172 | 173 | 175 | 177 | 179 | 179 | 185 | 182 | 174 | 160 |
Goodwill | -0.2% | 795 | 796 | 792 | 763 | 822 | 760 | 824 | 825 | 826 | 743 | 802 | 803 | 802 | 803 | 801 | 800 | 800 | 801 | 19.00 | 14.00 | 784 |
Liabilities | -5.0% | 433 | 456 | 503 | 432 | 436 | 496 | 512 | 501 | 510 | 333 | 336 | 387 | 396 | 416 | 509 | 494 | 507 | 534 | 541 | 507 | 554 |
Current Liabilities | -12.5% | 205 | 235 | 171 | 161 | 159 | 191 | 162 | 151 | 153 | 139 | 129 | 158 | 155 | 166 | 179 | 176 | 189 | 213 | 218 | 187 | 238 |
Long Term Debt | 4.9% | 167 | 159 | 258 | 203 | 205 | 226 | 248 | 249 | 254 | 130 | 145 | 165 | 175 | 180 | 249 | 248 | 248 | 248 | 248 | 248 | 248 |
LT Debt, Current | 9.3% | 9.00 | 9.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | - | - | - | - | - | - | 226 | - | - | - | 130 | - | - | - | - | - | - | - | 248 | - | - | - |
Shareholder's Equity | -0.7% | 1,228 | 1,236 | 1,222 | 1,235 | 1,651 | 1,291 | 1,264 | 1,259 | 1,633 | 1,271 | 1,267 | 1,302 | 1,257 | 1,262 | 1,290 | 1,262 | 1,257 | 1,273 | 1,267 | 1,277 | 1,280 |
Retained Earnings | -0.3% | -315 | -314 | -325 | -321 | -253 | -253 | -270 | -293 | -304 | -303 | -320 | -285 | -323 | -309 | -268 | -287 | -284 | -288 | -282 | -270 | -262 |
Additional Paid-In Capital | 0.2% | 1,668 | 1,664 | 1,660 | 1,655 | 1,651 | 1,646 | 1,642 | 1,637 | 1,633 | 1,629 | 1,626 | 1,621 | 1,617 | 1,609 | 1,604 | 1,600 | 1,596 | 1,594 | 1,592 | 1,587 | 1,583 |
Shares Outstanding | -0.2% | 46.00 | 46.00 | 46.00 | 47.00 | 47.00 | 47.00 | 46.00 | 47.00 | 47.00 | 48.00 | 48.00 | 48.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 1,192 | - | - | - | 1,279 | - | - | - | 1,748 | - | - | - | 1,403 | - | - | - | 2,076 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -163.0% | -8,000 | 12,700 | 29,100 | -2,600 | -6,800 | 33,700 | 28,400 | 27,000 | 1,800 | 52,100 | 23,200 | 15,300 | -3,300 | 1,100 | 1,100 | 1,100 | -5,800 | -2,900 | -16,600 | -31,900 | -23,100 |
Share Based Compensation | -10.0% | 3,600 | 4,000 | 3,900 | 3,900 | 4,000 | 4,000 | 4,100 | 4,000 | 3,800 | 3,000 | 3,500 | 3,600 | 3,100 | 3,200 | 3,400 | 3,000 | 2,500 | 1,700 | 2,800 | 1,800 | 4,200 |
Cashflow From Investing | -102.5% | -2,000 | 81,000 | -48,900 | -6,500 | -4,000 | -4,900 | -4,700 | -4,100 | -121,700 | -4,700 | -4,800 | -5,800 | -5,700 | -5,100 | -7,000 | -6,900 | -5,200 | -8,100 | -57,600 | -29,900 | -12,500 |
Cashflow From Financing | 99.4% | -700 | -114,700 | 46,700 | -4,100 | -22,100 | -21,900 | -10,200 | -16,900 | 105,700 | -25,800 | -19,200 | -10,100 | -200 | -68,300 | -2,000 | 300 | - | -100 | 2,500 | 800 | -1,700 |
Buy Backs | 46.8% | 9,100 | 6,200 | 9,200 | 2,600 | 1,100 | 400 | 11,000 | 14,700 | 19,400 | 10,900 | 100 | 500 | - | 500 | 100 | 300 | - | 200 | 100 | 1,400 | 1,900 |
CONDENSED CONSOLIDATED INCOME STATEMENTS - USD ($) $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Net Sales | $ 166.1 | $ 159.3 |
Cost of products sold | 71.3 | 67.9 |
Gross Profit | 94.8 | 91.4 |
Research and development | 7.0 | 7.5 |
Selling and general expenses | 83.6 | 88.8 |
Other expense, net | 0.2 | 1.2 |
Operating Income (Loss) | 4.0 | (6.1) |
Interest income | 0.6 | 0.5 |
Interest expense | (3.1) | (3.5) |
Income (Loss) Before Income Taxes | 1.5 | (9.1) |
Income tax (provision) benefit | (1.0) | 1.3 |
Income (Loss) from Continuing Operations | 0.5 | (7.8) |
(Loss) Income from discontinued operations, net of tax | (1.4) | 7.3 |
Net Loss | $ (0.9) | $ (0.5) |
Basic Earnings (Loss) Per Share | ||
Continuing operations- basic (in dollars per share) | $ 0.01 | $ (0.17) |
Discontinued operations- basic (in dollars per share) | (0.03) | 0.16 |
Basic Earnings (Loss) Per Share (in dollars per share) | (0.02) | (0.01) |
Diluted Earnings (Loss) Per Share | ||
Continuing operations- diluted (in dollars per share) | 0.01 | (0.17) |
Discontinued operations- diluted (in dollars per share) | (0.03) | 0.16 |
Diluted Earnings (Loss) Per Share (in dollars per share) | $ (0.02) | $ (0.01) |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 75.8 | $ 87.7 |
Accounts receivable, net of allowances | 131.3 | 142.8 |
Inventories | 165.6 | 163.2 |
Prepaid and other current assets | 28.6 | 28.8 |
Assets held for sale | 66.5 | 64.5 |
Total Current Assets | 467.8 | 487.0 |
Property, Plant and Equipment, net | 116.2 | 117.2 |
Operating Lease Right-of-Use Assets | 24.2 | 26.8 |
Goodwill | 794.9 | 796.1 |
Other Intangible Assets, net | 232.8 | 239.5 |
Deferred Tax Assets | 6.3 | 6.5 |
Other Assets | 19.1 | 19.3 |
TOTAL ASSETS | 1,661.3 | 1,692.4 |
Current Liabilities | ||
Current portion of long-term debt | 9.4 | 8.6 |
Current portion of operating lease liabilities | 11.5 | 12.8 |
Trade accounts payable | 57.0 | 56.3 |
Accrued expenses | 75.1 | 93.2 |
Liabilities held for sale | 52.2 | 63.7 |
Total Current Liabilities | 205.2 | 234.6 |
Long-Term Debt | 167.2 | 159.4 |
Operating Lease Liabilities | 26.6 | 28.3 |
Deferred Tax Liabilities | 23.6 | 23.8 |
Other Long-Term Liabilities | 10.8 | 10.0 |
Total Liabilities | 433.4 | 456.1 |
Commitments and Contingencies | ||
Stockholders’ Equity | ||
Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued | 0.0 | 0.0 |
Common stock - $0.01 par value - authorized 300,000,000 shares, 46,066,997 outstanding as of March 31, 2024 and 46,174,337 outstanding as of December 31, 2023 | 0.5 | 0.5 |
Additional paid-in capital | 1,667.7 | 1,663.6 |
Accumulated deficit | (315.8) | (314.9) |
Treasury stock | (95.0) | (85.9) |
Accumulated other comprehensive loss | (29.5) | (27.0) |
Total Stockholders’ Equity | 1,227.9 | 1,236.3 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 1,661.3 | $ 1,692.4 |